Clinical trials: Stage I Ovarian Cancer
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003382
- Testing
- filgrastim, gemcitabine hydrochloride, topotecan hydrochloride
- Where
- 6 sites in United States
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Fallopian Tube Cancer, Ovarian Cancer
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00903630
- Testing
- Lenalidomide, liposomal doxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Cognitive Impairment
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving…
- Trial name
- NCT04520139
- Testing
- N-Acetyl-Cysteine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of California, Irvine
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003380
- Testing
- etoposide, pegylated liposomal doxorubicin hydrochloride
- Where
- 63 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Cervix Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain…
- Conditions
- Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
- Trial name
- NCT06215950
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
HER2-positive Breast Cancer, Recurrent Breast Cancer
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
This phase I trial studies the safety and the ability to expand laboratory-treated T cells when given together with cyclophosphamide or denileukin diftitox in treating patients with human epidermal growth factor receptor…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00228358
- Testing
- ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Ovarian Cancer
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Trial name
- NCT05922930
- Testing
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Epithelial Ovarian Cancer
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed…
- Trial name
- OVHM-01 (NCT00889733)
- Testing
- Intraperitoneal (IP) Cisplatin
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Cancer
Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer
RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer.
- Trial name
- NCT00049465
- Testing
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Where
- 9 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00702299
- Testing
- cisplatin, paclitaxel, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona